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ABSTRACT Advanced microbiology technologies are rapidly changing our ability to
diagnose infections, improve patient care, and enhance clinical workflow. These
tools are increasing the breadth, depth, and speed of diagnostic data generated per
patient, and testing is being moved closer to the patient through rapid diagnostic
technologies, including point-of-care (POC) technologies. While select stakeholders
have an appreciation of the value/importance of improvements in the microbial di-
agnostic field, there remains a disconnect between clinicians and some payers and
hospital administrators in terms of understanding the potential clinical utility of these
novel technologies. Therefore, a key challenge for the clinical microbiology community is
to clearly articulate the value proposition of these technologies to encourage payers to
cover and hospitals to adopt advanced microbiology tests. Specific guidance on how to
define and demonstrate clinical utility would be valuable. Addressing this challenge will
require alignment on this topic, not just by microbiologists but also by primary care and
emergency room (ER) physicians, infectious disease specialists, pharmacists, hospital ad-
ministrators, and government entities with an interest in public health. In this article, we
discuss how to best conduct clinical studies to demonstrate and communicate clinical
utility to payers and to set reasonable expectations for what diagnostic manufacturers
should be required to demonstrate to support reimbursement from commercial payers
and utilization by hospital systems.
KEYWORDS clinical utility, evidence, health economics, molecular methods,
outcomes research, reimbursement
Until recently, clinical microbiology diagnostic techniques have relied almost exclu-sively on culture and isolation of microbes from patient specimens, with biochem-
ical and phenotypic analysis to identify pathogen(s) causing infections (1–3). While
creating the infrastructure for clinical laboratory scientists to perform culture and
conduct analyses was costly, once well established, these techniques are inexpensive
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and can be highly standardized. Unfortunately, these techniques are time consuming,
typically requiring 2 to 5 days or more to identify pathogens. In select cases, culture
techniques may fail to adequately grow certain etiologic agents (e.g., Mycoplasma
pneumoniae) or detect a viral pathogen. While developments in this space have
historically focused on automating the culture process to reduce hands-on time and
overall turnaround times to diagnosis, the turnaround time remains slow, which often
causes physicians to treat empirically before diagnostic confirmation. Extended empir-
ical treatment time may lead to the inappropriate use of antimicrobials, which may
further contribute to the growing burden of antibiotic resistance. Studies have esti-
mated that 30% to 50% of prescribed antimicrobials may be overprescribed or unnec-
essary (4, 5), which may contribute to the spread of infections due to increased
antimicrobial resistance. Use of systemic antibiotics can lead to a disruption in the
microbiome that can result in diarrhea and other complications (6, 7). One study
concluded that some 20% of patients receiving antibiotics experienced an adverse drug
event (8). The goal, therefore, is to avoid unnecessary antibiotics in addition to getting
the patient on the most appropriate antibiotics when necessary.
In recent years, the introduction of new technologies has positively impacted both
the diagnosis and treatment paradigms for infections. These tools are in the process of
revolutionizing clinical microbiology testing in various settings. These include technol-
ogies such as matrix-assisted laser desorption–ionization time of flight mass spectrom-
etry (MALDI-TOF MS), multiplex molecular diagnostic panels, and innovations that bring
nucleic acid amplification testing to the point of care. The proteomic-based technology
MALDI-TOF MS has seen wide adoption, particularly among academic hospitals. While
this method still requires isolation and culture of pathogens, MALDI-TOF MS allows for
the identification of a specific microbe based upon its unique proteomic fingerprint (9,
10). MALDI-TOF MS has led to significant time and cost savings, as correct diagnoses are
made more rapidly without the need for additional confirmatory tests. Multiplex
molecular diagnostic panels (11, 12) are also being introduced more commonly for a
variety of conditions, including sepsis and nonspecific syndromes, such as respiratory or
gastrointestinal (GI) infections. Multiplex assays can combine tests for numerous patho-
gens and resistance markers in a single panel, which can significantly reduce the time
to diagnosis and, in select situations, bypass the need for culture. Furthermore, im-
provements in engineering and technology have also led to the development of
improved point-of-care (POC) tests (13–16), which are poised to significantly impact the
future treatment paradigm for many infectious conditions, such as viral respiratory
infections and sexually transmitted infections (STIs). Low-complexity POC tests allow for
nonlaboratory personnel (e.g., nurses and physician assistants) to conduct tests at the
initial site of care, potentially allowing physicians to administer the therapy at the initial
consultation and eliminating the need for follow-up assessments.
These tools have the potential to address many key challenges in the field of
infection management by reducing the time to diagnosis and informing earlier thera-
peutic decisions, which may improve clinical decision making, patient outcomes,
workflow, and antimicrobial stewardship (5, 17–19). These types of innovations also
have the potential to significantly improve both individual patient outcomes and
broader public health by facilitating better tracking of pathogens and changes in/
development of antibiotic resistance (2).
However, in many cases, the clinical deployment of these technologies has been
restrained by skepticism from payers and hospital administrators over clinical, and
ultimately cost, benefits. Select referenced studies are underpowered from a statistical
perspective, which may not demonstrate a benefit as clearly as would be desired. In
some cases, advanced microbiology tests provide limited improvement in accuracy
over standardized laboratory culture-based tests, although they provide workflow and
efficiency benefits. Therefore, it is imperative to demonstrate robust evidence of clinical
utility in a timely and cost-effective manner to increase our understanding of the
benefits of adoption of advanced microbiology tests across care settings. More robust
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studies of clinical utility will also improve our knowledge of the impact on clinical
outcomes and operations, which can lead to enhancements in care.
OVERVIEW OF CLINICAL UTILITY AND EVIDENCE DEVELOPMENT
CONSIDERATIONS
Clinical utility of a test is related to the added value it has for patient management.
A test has utility if its results (positive or negative) provide information that is of value
to the patient and the provider in making decisions about effective clinical care. It can
take the form of improved efficiency in clinical decision making, streamlined clinical
workflow, better patient outcomes, and/or cost offsets or avoidance (20–24). The level
of clinical utility evidence required will likely depend upon a variety of factors, including
the current standard of care (SOC), the setting of care, and potential cost offsets to
mitigate the added cost of care, as well as the magnitude of the cost of the test itself.
Clinical utility, in the microbial space, is considered to include instances in which
new approaches can inform treatment decisions by providing information to key
stakeholders, such as the patient, physician, and payers, to diagnose, monitor, and/or
predict disease progression. For example, rapid POC influenza testing has been shown
in several studies to significantly reduce prescriptions of antimicrobials and increase
prescriptions of oseltamivir (Tamiflu) in outpatient care clinics (25–27). Rapid POC
influenza testing can improve antibiotic stewardship and positively impacts patient
management via a faster resolution of flu symptoms. Better initial treatment decision
making could also influence important outcomes, like morbidity and mortality, for
at-risk patient populations, such as the elderly and immunocompromised.
It is important to note that a necessary first step for any new diagnostic is to
demonstrate that it meets, and potentially surpasses, the bar for accuracy of the current
SOC. However, accuracy alone does not, in and of itself, demonstrate clinical utility.
Instead, it is a prerequisite for utilization that facilitates impact on clinical care, which
can then translate into clinical utility.
It is important that microbiologists conducting clinical utility studies consider which
type of trial is most appropriate for the technology and endpoint they wish to study,
as well as the ultimate stakeholder audience for the diagnostic technology. Whenever
possible, studies designed to generate evidence of clinical utility should consider the
needs of potential patient populations. For instance, hospital administrators often look
for evidence generated in a system that closely resembles their organization, to provide
confidence that the clinical utility demonstrated in a trial may translate to real-world
experience. Also, many hospital systems may conduct their own trials with new
diagnostic technology, to provide real-world evidence for improved workflow, decision
making, and patient care resulting from the adoption of new technology. Published
results are impactful for commercial payers when they can demonstrate clear changes
in clinical decision making for patients that are representative of their plan members
that were directly facilitated by the information provided by the test. Ideally, payers
would like to see data demonstrating that these decisions correlated with positive
clinical outcomes. However, payers are aware that many factors go into clinical out-
comes beyond the diagnostic result, and therefore it may be sufficient to simply show
a connection between the changes in decision making and potential clinical outcome.
Once the audience is defined, the study designers also need to determine the
appropriate level of evidence. The key considerations are the overall size of the trial and
its representativeness. The size of the trial relates to the relative rarity of the events that
occur. Statistical power calculations can be done to determine the number of patients
needed relative to the delta in a change of endpoint. As the numbers of groups of
patients and parameters to be measured increase, the number of patients needed to
achieve a significant result will also increase. For instance, a study that measures only
one patient group (e.g., high risk for respiratory conditions) with two diagnostic arms
(e.g., SOC compared to multiplex panels) may be able to reach significance with 100
patients. A trial that was following three cohorts of patients (e.g., high risk, low risk, and
the general population) and measuring three diagnostic arms (e.g., culture and phe-
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notype, single-gene PCR tests, and multiplex molecular panels) would likely require 800
or more patients (28, 29). A study of this complexity and size may not be feasible for
many clinical labs.
To illustrate representativeness, it is important to conduct the trial at a location
which is comparable to the broader clinical community. For instance, by testing
MALDI-TOF MS technology in large academic hospitals with a significant volume of
testing, the investigators were able to demonstrate the significant clinical utility
of MALDI-TOF MS to improve workflow and decision making in central laboratories of
major hospital systems (30, 31). When researchers conduct studies in hospital systems
with a unique patient population or practices, it may be challenged by payers and
others as being nonrepresentative.
OVERVIEW OF CLINICAL UTILITY EVIDENCE DEVELOPMENT CONCEPTS
While overall clinical utility for microbial diagnostics covers the areas defined above,
the value proposition of technology may typically be demonstrated by impacting one
or more of the following categories: clinical decision making, clinical workflow, patient
outcomes, and clinical costs (Fig. 1).
The first step is defining the current standard of care; researchers should always
strive to test clinical utility in comparison to the current SOC, with the goal of
significantly improving at least one step of the diagnostic paradigm. Therefore, micro-
biologists should carefully study the SOC and determine where the new test can make
the most significant improvement (32). If current care is well defined, an observational
trial measuring changes in care could be sufficient. If the current SOC is not well
defined, these types of studies will be most effective if they are large prospective
studies over multiple institutions, allowing for the determination of the clinical utility of
such a test in a variety of settings with different care paradigms.
Researchers can demonstrate clinical utility through a variety of trial designs (33),
including randomized control trials (25, 34), in which patients are randomly assigned as
they enter the health care system to a new diagnostic being tested or to the SOC (Fig.
2). At the end of the study period, the researchers can ascertain how measured
endpoints varied between the two groups. Prospective interventional or observational
FIG 1 Endpoints for studies of clinical utility.
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trials (17, 19, 35, 36) are conducted by measuring a specific endpoint(s) for a selected
length of time before introducing the new diagnostic. After the new diagnostic has
been established, the same endpoint(s) will be measured over a similar period so that
changes caused by the diagnostic can be ascertained. Retrospective analysis trials
(37–39) are conducted once a test has been widely deployed for an extended period of
time; researchers can then gather historical data for the endpoint(s) either prior to the
deployment of the test or from locations where it has not been deployed and compare
these endpoint data to data from similar institutions where the test is in place. Finally,
one can collect information about the impact of test on clinical decision making using
a pretest/posttest survey instrument. In this type of study, a physician is asked to record
their current care plan based on available information. They are then presented with
the test results and asked if their decision would change. Pretest/posttest survey
instruments are helpful in that they capture the actual shifts in thinking that occurs as
a result of the test, but it is limited in that it does not track actual behavior or outcomes
moving forward.
Although a particular trial design may be more appropriate for a select technology
or setting of care, all of these types of trials can be appropriate ways to demonstrate
clinical utility. Historically, randomized control trials have been considered the gold
standard for evidence generation and still are in many circumstances, especially for
pharmaceutical agents. Select commercial payers, likely informed by their experience
with pharmaceuticals, may expect randomized control trials for advanced microbial
diagnostics, although there is a growing understanding that each of the trial types has
advantages in certain situations but may not be required or may have limitations in
others. For example, it is difficult to execute a diagnostic trial with a “placebo” test. In
particular, diagnostic tests can show their value through retrospective and prospective
observational studies, in which researchers compare the care delivered by a novel
technology to a historical standard of care.
Clinical decision making. Improvements in clinical decision making are often the
primary endpoint of diagnostic studies, due to both feasibility and the fundamental
purpose of diagnostics, which is to inform better the treatment choices physicians
make. It is important to note that improved clinical decision making can create value
by not just improving therapy decisions and supporting antibiotic stewardship efforts
but also through conserving resources (e.g., faster emergency room [ER] triage, or
removing patients who do not have communicable infections from isolation rooms).
When studying changes in clinical decision making resulting from the implemen-
tation of new technologies, common endpoints that may be examined include mea-
suring time to initiation of appropriate therapy, time to initiation of antibiotic
escalation/de-escalation protocols, degree of expedited ER triage for hospital admission
or discharge, the time patients spend in isolation rooms, and effective antibiotic
FIG 2 Select examples of types of trials that can be used to demonstrate clinical utility.
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stewardship metrics. For instance, several successful studies have been completed
using MALDI-TOF MS in central hospital laboratories, demonstrating changes in types
of antimicrobials prescribed and reduced time to placing patients on appropriate
antibiotic regimens (19, 35, 40, 41).
Technologies that impact the removal of patients from isolation rooms or critical
treatment decisions (e.g., for patients with sepsis) need to show statistical impact for
instances and causation for important decisions (4, 17, 19). For example, a recent study
of improved decision making from new diagnostic technology in the management of
sepsis showed via a randomized controlled trial that multiplex panels have hastened
the diagnostic process and led to the faster placement of patients on appropriate
antimicrobials (40). These changes in decision making result in, at a minimum, improve-
ment in antibiotic stewardship, and they may over a longer time frame reduce
mortalities related to sepsis (34, 42, 43).
As technologies become more widely used or are being applied to more common
decision points, retrospective and prospective studies become more feasible and are
easier to execute. For example, the greatest utility of POC influenza tests for changing
clinical decision making is evident with studies in ERs, primary care physician offices,
and outpatient clinics, by showing reductions in empirical antibiotic treatment and
increases in Tamiflu prescriptions in these clinical settings through larger retrospective
and prospective studies (25, 44, 45). Similarly, a study of a gastrointestinal panel
showed reduction of several patient days on antibiotic and in the length of time to
discharge (46). In the future, multiplex syndromic panels for outpatients may develop
evidence of clinical utility by targeting specific high-risk groups, such as immunocom-
promised and pediatric patients and elderly patients in assisted living facilities. Hospital
admission is a critical decision point for these patients and therefore a potential
endpoint; expediting hospitalization of patients with severe infections may significantly
improve health outcomes. Furthermore, some patients with less severe infections may
benefit from avoiding hospital admission, limiting the potential of nosocomial infec-
tions and avoiding the sizable cost of hospitalization. Information about the use of
these technologies can be collected through collaborative efforts in multiple institu-
tions or from a single institution that works with high volumes of vulnerable patients.
Clinical workflow. Clinical workflow is substantially different in the outpatient and
inpatient settings and typically is of higher priority for inpatient services. For hospitals,
enhancing clinical workflow has the potential to significantly improve patient care and
lead to lower costs, particularly as more complex and/or labor-intensive tests may be
replaced with simpler and/or more efficient tests. Also, such improvements can aid
hospitals in meeting important quality metrics, such as limiting hospital-acquired
infections and improving antimicrobial stewardship. Improvements in the workflow can
be accomplished by streamlining the diagnostic process or by more rapidly monitoring
changes in antimicrobial resistance or types of pathogens present (19). Many hospital
central laboratories are limited to running tests for select pathogens at certain times of
the day and/or week, due to the complexity of tests which require highly trained
technologists to perform the assays. Also, there may be periods of higher volumes (e.g.,
influenza season, disease outbreak, etc.) where central laboratories can be over-
whelmed by the workload. High-volume laboratory demands can have further down-
stream impacts, including delaying the ability for other diagnostic tests and clinical
services in the hospital to be efficiently run. New advanced microbial testing tools offer
the potential to significantly improve workflow in both outpatient clinics and labora-
tories by decreasing the time and technical expertise required to perform each test.
Also, advanced technologies may allow an increased number of patient samples to be
tested simultaneously, thereby increasing efficiency and throughput of the laboratory,
resulting in improved workflow and faster results. Unfortunately, clinical workflow is
rarely quantified and reported in the literature, making comparisons across institutions
difficult. More studies in this area would significantly benefit the field. Relevant end-
points tested for clinical workflow could include time to reaching a confirmed diagno-
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sis, number of tests that must be run for diagnosis, clinical laboratory hours worked per
diagnosis, number of samples the laboratory processes per unit time, and the frequency
at which backlogs develop in the laboratory. Furthermore, it is important to note that
the United States is currently facing a shortage of trained clinical laboratory personnel
that is not expected to improve in the immediate future. Technologies that allow fewer
technicians to run more tests will likely play an essential role in overcoming this
challenge (47–49).
One of the most significant ways for improvements in outpatient workflow clinical
utility is to show that clinics can triage patients faster and thereby increase the volume
of patients assessed and treated in a similar time frame. Increasing the volume of
patients a physician can see in a select amount of time has the potential to improve
patient access by allowing a physician to see more patients per day (50, 51). For
example, when a POC test identifies a patient requiring immediate treatment while also
identifying individuals that are safe to release, it could significantly improve workflow
by diagnosing and treating patients in a single visit without the need for follow-up
assessments if the diagnosis is delayed (e.g., sexually transmitted infection [STI] tests,
HIV, influenza, group A Streptococcus, etc.). POC tests can not only identify patients with
severe infections that need to be admitted to the hospital but can also identify patients
with more minor conditions that are candidates for discharge and therefore reduce
occupation of ER beds (50, 51). One key consideration is that often these decisions are
made quickly, so to impact clinical workflow, the results must be made available within
a limited time frame (e.g., during or immediately after the visit). Prospective or
retrospective studies may be sufficient to demonstrate altered patient flow due to the
utilization of a new diagnostic technology. Appropriate endpoints for outpatient
workflow could include time to diagnosis for outpatients, number of patients seen,
number of tests/diagnostic procedures performed, duration of visit per patient, and
frequency for which follow up visits are needed. An example of this type of study can
be found in a recent publication describing a randomized control trial in which the
benefits of same-day testing for chlamydia and gonorrhea were evaluated compared to
SOC testing (2- to 3-day turnaround time). In this study, there was 0% undertreatment
compared with 43.8% for patients tested by the SOC. (52) A retrospective study of a
multiplex molecular gastrointestinal (GI) testing panel showed not only a reduction in
antibiotic prescription but also fewer endoscopic and abdominal radiology procedures
(46).
Patient outcomes. Patient outcomes are a central focus of medical studies and are
typically focused on reductions in morbidity and mortality. Microbial diagnostics may
meaningfully improve patient outcomes, as a more rapid diagnosis will likely directly
impact timely clinical decision making and improve overall patient care (19, 36, 53, 54).
While these benefits may represent evidence for clinical utility, it is often difficult to
demonstrate that improved outcomes are specifically due to the diagnostic test, given
the multitude of factors associated with patient therapeutic response. The diagnostic
tool itself should only be held to the standard of informing the correct treatment
decision and should not be required to prove that the therapeutic positively impacts
care, as limitations in the treatment can overwhelm improvements in diagnostics and
many benefits of decision making (e.g., antibiotic sparing) will not result in morbidity
and mortality improvements. It should be a given that when a pathogen is correctly
identified and the optimal treatment is initiated that an improvement has occurred,
whether or not this translates into a measured direct reduction in morbidity and
mortality. Therefore, the most appropriate approach may be for diagnostic developers
to demonstrate an improvement in clinical decision making for reimbursement.
These efforts can initially be focused on the demonstration of clinical utility in
smaller patient populations that are more likely to benefit from diagnostic improve-
ments, such as infants, immunosuppressed or compromised patients, and the elderly.
For instance, multiplex molecular syndromic panels might show significant improve-
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ments for immunocompromised patients by quickly identifying those that should be
treated immediately for serious infections.
Clinical outcomes are of paramount importance to both inpatient and outpatient
care. However, the particular outcomes desired can be different in each setting. For
inpatient care, the most common desired outcomes will be reducing the length of
hospital stay, the time patients spend in the intensive care unit (ICU), readmissions, and,
ultimately, infection-associated mortality. For example, MALDI-TOF MS, when con-
ducted post positive blood culture has shown a reduction in mortality for patients with
sepsis in prospective interventional trials (19). However, in the inpatient setting, patient
outcomes may be dependent on multiple factors other than diagnostics, particularly for
more serious infections or for patients with complex comorbidities. Studies of patient
outcomes, therefore, are often assessed with prospective or retrospective clinical trials,
as they will need to be conducted over several institutions or conducted for long
periods of time to generate sufficient statistical power to reach conclusions on a
diagnostic-specific impact on patient outcomes.
For outpatient care, critical endpoints regarding patient clinical outcome include
situations in which the identification and management of infections avoid hospitaliza-
tion and development of more serious conditions. In many circumstances, changes in
clinical decision making that would reasonably be expected to improve outcomes
along with hospital admission rates will be appropriate endpoints. However, once a
diagnostic is widely used in the outpatient setting, large retrospective studies over
many medical systems using the technology will likely be feasible.
Cost-benefit evaluation. Underlying each of these categories is a fundamental
question about whether the additional clinical benefits can be justified from a financial
perspective. In the United States, this takes the form of cost/impact and simple return
on investment analysis rather than formal cost-effectiveness evaluations as seen in
other markets. Advanced technologies usually come at some additional cost, but they
have the potential to free up resources by reducing the use of other tests, or by
avoiding additional diagnostic procedures. It is worth remembering that different
stakeholders in the hospital may be motivated by different cost-benefit considerations;
for instance, laboratory directors may be interested in how cost translates to efficiency,
while C-suite executives will likely focus more on return on investment.
In the inpatient setting, cost will be less of a concern because inpatient care is
focused on more serious infections with severe/costly outcomes. Also, there are more
ways for costs to be offset in inpatient care. For instance, studies with multiplex
gastrointestinal panels have shown some ability to reduce cost by removing patients
from high-cost isolation rooms and moving them to general wards when the patients
were shown not to have communicable infections (5). Other studies have shown cost
reductions through fewer diagnostic testing/imaging studies and reduced length of
stay, not only in GI patients but in those with the respiratory virus as well (46, 55).
Another example is the use of MALDI-TOF MS, which has routinely demonstrated lower
costs per sample than culture and phenotype assays for organism identification.
However, the high upfront cost of MALDI-TOF MS instruments means these savings
might only be realized by high-volume laboratories. Appropriate endpoints for mea-
suring cost are direct spending changes in dollars, but more sophisticated health
economic modeling showing differences in quality-adjusted life years/incremental
cost-effectiveness ratios may be justified (4). It is worth noting that cost avoidance is
often harder to quantify and track than direct costs and revenue, which makes cost
savings benefits from a test more difficult to communicate to payers and users.
For outpatient care, direct costs are unlikely to show clinical utility, as tests will be
compared to relatively inexpensive methods with limited ability to create offsets. In this
situation, cost becomes a barrier, leading commercial payers to be less enthusiastic to
reimburse a test because of the negative economic impact it may have. Of particular
note, high-priced tests are more likely to be held to higher evidentiary thresholds by
commercial payers, who may demand larger clinical trials or randomized control trials,
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when at a lower price point prospective observational or retrospective trials would
have been accepted.
DISCUSSION OF WAYS TO FOSTER CLINICAL UTILITY EVIDENCE DEVELOPMENT
AND INNOVATION
Role of evidence. To effectively maximize clinical uptake and broad payer coverage
of advanced technologies, the microbiology community must collectively form an
action plan involving a variety of stakeholders to collaborate and demonstrate the
beneficial effects of advanced technologies in the management of infectious diseases.
A key starting point for collaborative efforts in the microbial diagnostic space would be
to conduct studies to determine the economic and clinical challenges and limitations
of the current diagnostic paradigm. Properly conducted studies on this topic could help
persuade payers of the potential room for growth in this area and will set the stage for
the possible benefits of new technologies that can result in improvements in patient
care.
Key stakeholders should work closely with publishers of clinical guidelines to
articulate the role and best practices for the use of these tools to better inform payers
on the value and practicality of new tests. The continued generation of appropriate
clinical data may also lead to a willingness to include advanced technologies in
published guidelines. Including new diagnostic technologies in clinical guidelines
would add significant value, particularly in the eyes of payers, who refer to published
guidelines to inform their decision on whether to reimburse a technology. Clear
guidelines are particularly important for those technologies where the added cost of a
technology is currently perceived as a limitation for wide adoption in routine practice
(e.g., next-generation sequencing [NGS] technologies for microbiology).
Prioritizing clinical utility evidence generation by hands-on users in real-world
settings, such as improved impact on everyday clinical decision making and individual
patient outcomes, will be important to drive the future value proposition of advanced
microbiology technologies. While this additional evidence will likely play a major role
in facilitating broader utilization of new diagnostics among health care entities, it will
also educate payers on the added value to encourage broader payer coverage and
reimbursement.
It may be possible to eventually demonstrate outcomes not only at the individual
patient level but also at the population level. For example, there is potential to show
that outcomes are improved via public health benefits that result from better antibiotic
selection and community-acquired resistance management through the regional ap-
plied use of advanced diagnostic technologies. The full benefits of these technologies
will only be realized once antimicrobial stewardship and operational improvements
(e.g., strain tracking, hospital infection control surveillance, etc.) are applied in aggre-
gate. This will require a greater collaborative/coordinated effort across multiple insti-
tutions potentially coordinated by a public health entity. These types of studies will
require collaboration between many stakeholder organizations, such as the American
Society of Microbiology (ASM), clinical and physician societies, and government groups.
When these types of studies are conducted, positive results should be utilized to
encourage the Centers for Disease Control and Prevention (CDC) to publish formal
guideline updates encouraging widespread adoption of a diagnostic technology, given
the significant improvements in patient outcomes and potentially in public health.
Role of the microbiology and infectious disease community. As noted above,
many of the forms of clinical utility require showing the impact on clinical decision
making; therefore, it is important for microbiologists to understand how clinical deci-
sion making is done in the current SOC by engaging clinicians managing infections.
Success in developing clinical utility information will require microbiologists building
bridges to members of the clinical community. The clinical stakeholders needed include
not only infectious disease specialists but also infection control practitioners and
primary care and emergency room physicians to determine the impact of these tools
on everyday care. Better coordinated action requires findings consensus about the key
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benefits and required evidence and jointly and clearly articulating this information to
key stakeholders, such as hospital administration and payers.
A role for industry. Both the pharmaceutical and diagnostic manufacturing indus-
tries will also be required to be involved in orchestrating the generation of clinical
utility evidence. Given that hospital administrators often prefer to undertake a trial
period with new technologies to gain first-hand experience, diagnostic technology
manufacturers may need to pursue collaborations for this to be actively achieved.
Furthermore, they can work to guide not only microbiologists but also facilitate early
partnership with those in clinical and financial roles about the design of studies which
could help illustrate the clinical utility of these deployed tools in a fair and balanced
way. They can also play a role in helping community hospitals understand where to find
clinical utility information and how to share clinical utility information so that advanced
care approaches are not limited to academic medical centers. This support can come in
the form of research grants that are specifically for utilization reviews rather than for
traditional clinical trials. Critically, the microbial diagnostic industry should recognize
that efficacy and clinical utility trials conducted by industry are often viewed skeptically
by clinicians and payers. A better solution may be to provide funding to institutions
using the technology to support studies of clinical utility and best practices that the
institutions can publish independently.
Additionally, pharmaceutical leaders in the microbiology space may be required to
actively participate in data gathering and publication supporting the concept that
next-generation antimicrobials may be more effective, particularly if paired with the
most advanced diagnostic technologies. This will likely require active collaboration
between pharmaceutical and diagnostic companies to ensure the clinical utility benefit
of appropriate prescribing of next-generation treatments is influenced by novel tech-
nologies entering the space. The National Institutes of Health (NIH) and the CDC have
the potential to facilitate and mediate these types of collaborations through improving
communications, providing funding for important studies, promoting a strong clinical
research environment, and supporting inclusion in clinical guidelines when tests are
shown to be effective and economical.
A role for government and advocacy. Demonstrating the value of novel micro-
biology technologies will likely require a holistic approach to be undertaken by the
microbiology community. Engaging key agencies, such as the CDC and NIH, to increase
funding for large studies to generate large data sets of evidence will be a key strategy
to articulate the message. Such studies involving a variety of stakeholders should aim
to demonstrate improved antibiotic stewardship, patient outcomes, and communicate
the overall economic and health benefits for the community following the adoption of
novel microbiology technology in the future. For example, the CDC has responded to
the U.S. National Action Plan for Combating Antibiotic-Resistant Bacteria by launching
initiatives such as Antibiotic Resistance (AR) Solutions, which involves investments in
national infrastructure to prevent resistant infections (https://www.cdc.gov/drugresistance/
solutions-initiative/index.html). We urge the CDC to include evaluation of advanced
diagnostic technologies as potential tools to improve antimicrobial stewardship, clinical
decision-making/workflow, clinical outcomes, and the detection, tracking, and preven-
tion of resistant infections.
Professional societies, such as ASM, will likely play a key role in developing close
working relationships with government organizations, such as the NIH and CDC, to
emphasize the value of clinical utility of advanced microbial diagnostics. Importantly,
these groups should focus on supporting the development of evidence and sharing of
information in areas that are not a high priority to any single stakeholder to help
resolve collective action issues. Moreover, demonstrating robust clinical utility will likely
require clinical microbiologists to engage with each stakeholder type, from a variety of
physician groups to hospital administrators and payers, to aid understanding and
communicate the potential benefit that advanced microbiology tools provide in various
care settings. These improvements may be achieved by improving not only the speed
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and accuracy of disease diagnosis but also key characteristics such as workflow and cost
avoidance (32).
Implications for future incorporations of technology. The advances and innova-
tions in microbial diagnostic technologies over the last decade are beginning to have
a significant impact on the way we diagnose and manage infectious diseases. In the
coming years, an additional cohort of new microbial diagnostics is expected to enter
the space. Technologies that include advanced genomics (56, 57), proteomics, and
rapid susceptibility tests (58) are expected to cause dramatic changes by tackling some
of the most important problems for microbial diagnostics. Additionally, advanced
analytic tools, such as artificial intelligence and machine learning, can enhance the
information extracted from the data these technologies collect (49, 59, 60).
For example, the menu of culture-independent nucleic acid amplification tests and
syndromic panels is expanding. These advances will likely favor the deployment of
culture-independent reporting of antimicrobial resistance (AMR) determinants, includ-
ing the creation of a clear correlation of AMR genotype to antimicrobial susceptibility
phenotype/MICs. Also, automated microscopy is being leveraged for early detection of
sepsis by detection of morphological changes in monocytes indicative of dysregulated
immune response or morphological changes in bacteria indicative of drug susceptibility
(61).
Next-generation sequencing methods and proteomics (e.g., MALDI-TOF) are ex-
pected to impact key diagnostic segments in the future. In contrast to PCR panels, these
methods have the potential for “hypothesis-free” detection of pathogens and host
response markers. NGS-based analysis of pathogens further allows phenotypic predic-
tion, such as detection of AMR determinants, virulence factors, and mobile genetic
elements. Also, whole-genome sequencing of isolates by next-generation sequencing
allows strain typing at nucleotide-level resolution for epidemiological studies and
infection control. These methods have tremendous potential in the clinical microbiol-
ogy lab, opening a novel paradigm for diagnostics.
However, to be deployed clinically and realize this potential, these technologies will
need to build on efforts associated with more established technology that has dem-
onstrated clinical utility. Our hope is that the concepts outlined throughout this paper
will facilitate the demonstration of the clinical utility of recently launched novel
methods so that the even newer tools and techniques, as described above, will be able
to find a pathway to success and routine application in the clinical microbiology
laboratory. Adoption of these technologies may also require hospitals and payers to
place a higher priority on infection control than they do currently and to support their
infection control centers.
CONCLUSION
The need for improvements in microbial diagnostics and thereby in management of
infectious disease is clear and urgent. This need has the potential to be filled by a
combination of new technologies that have entered the diagnostic space or will enter
it shortly. However, there is a clear gap in the field that is preventing these technologies
from being widely deployed to fill the current unmet clinical need for rapid and
improved testing. While the necessity of deploying better microbial diagnostics is not
lost on microbiologists and infectious disease specialists, other key stakeholders have
lower awareness. Therefore, a collective effort is needed from microbiologists and
clinicians handling infectious diseases to communicate to other stakeholders the costs
and downsides of the current SOC. Demonstrating and communicating how the low
cost of phenotypic methods is often offset by the high cost of preventable morbidity
and mortality that comes from a slow diagnostic SOC, and how new tests can directly
impact and improve clinical decision making, is needed. Clearly defining and describing
these issues to commercial payers, hospital administrators, and government regulators
will smooth the deployment of these technologies and benefit individual and commu-
nal health.
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